Drug Trial Radar · NCT05937386
Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Aug 9, 2023
Primary completion
Sep 6, 2023
Study completion Sep 6, 2023
Sponsor
- Lead sponsor
- Agomab Spain S.L.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, open-label, fixed-sequence, Phase 1 study in healthy adult participants to evaluate the effect of AGMB-129 on the PK of a single dose of MDZ in healthy participants. A total of 14 participants will be enrolled and will receive study intervention in a fixed-sequence scheme. All IP will be administered orally and in fed conditions. The total duration of involvement for each participant, screening through follow-up, will be approximately 6 weeks.
Conditions
- Healthy Volunteers
Interventions
AGMB-129Drug
Oral capsule
MDZDrug
Pre-filled oral syringes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax for MDZTime frame: Day 1 to Day 13
- Cmax for 1-OH-midazolamTime frame: Day 1 to Day 13
- AUC0-∞ for MDZTime frame: Day 1 to Day 13
- AUC0-∞ for 1-OH-midazolamTime frame: Day 1 to Day 13
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SGS Belgium
Edegem, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.